Postprandial platelet activation is related to postprandial plasma insulin rather than glucose in patients with type 2 diabetes
Galia Spectre, Claes-Göran Östenson, Nailin Li, Paul Hjemdahl, Galia Spectre, Claes-Göran Östenson, Nailin Li, Paul Hjemdahl
Abstract
Postprandial hyperglycemia is associated with platelet activation. We thus investigated if meal-induced platelet activation could be attenuated by meal insulin. A randomized, double-blind, cross-over study was performed to compare postprandial platelet activation after premeal injections of placebo or insulin aspart (0.1 and 0.2 units/kg) in 18 patients with type 2 diabetes mellitus (T2DM). Platelet activation was assessed by flow cytometry, without and with stimulation by the thromboxane analog U46619 or ADP. Measurements were before and after premeal blood glucose standardization (to 6-7 mmol/L by insulin infusion, if needed) and at 90 min after the meal. Premeal insulin reduced postprandial hyperglycemia by 2-3 mmol/L compared with placebo. Postmeal insulin levels were doubled with placebo and further elevated with insulin injections. The standardized meal enhanced U46619-induced platelet P-selectin expression by 23% after placebo; this response was more than doubled after premeal insulin. U46619-induced fibrinogen binding was unchanged after meal intake with placebo but was markedly enhanced (by ~50-60%) after premeal insulin. Postprandial platelet activation correlated positively to postprandial insulin levels and inversely to glucose levels. Premeal insulin infusion was also associated with platelet activation. Our results suggest that postprandial insulin rather than glucose accounts for postprandial platelet activation in T2DM patients.
Trial registration: ClinicalTrials.gov NCT00771693.
Figures
References
- Aryangat AV, Gerich JE. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. Vasc Health Risk Manag 2010;6:6145–155
- Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681–1687
- Ceriello A, Cavarape A, Martinelli L, et al. The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004;21:171–175
- Yngen M, Östenson CG, Hjemdahl P, Wallén NH. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. Diabet Med 2006;23:134–140
- Razmara M, Hjemdahl P, Yngen M, Ostenson CG, Wallén NH, Li N. Food intake enhances thromboxane receptor-mediated platelet activation in type 2 diabetic patients but not in healthy subjects. Diabetes Care 2007;30:138–140
- Santilli F, Formoso G, Sbraccia P, et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost 2010;8:828–837
- Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007;77:280–285
- Li N, Wallén NH, Hjemdahl P. Evidence for prothrombotic effects of exercise and limited protection by aspirin. Circulation 1999;100:1374–1379
- Hu H, Li N, Ekberg K, Johansson B-L, Hjemdahl P. Insulin, but not proinsulin C-peptide, enhances platelet fibrinogen binding in vitro in Type 1 diabetes mellitus patients and healthy subjects. Thromb Res 2002;106:91–95
- Farndale RW, Lisman T, Bihan D, et al. Cell-collagen interactions: the use of peptide Toolkits to investigate collagen-receptor interactions. Biochem Soc Trans 2008;36:241–250
- Massucco P, Mattiello L, Russo I, et al. High glucose rapidly activates the nitric oxide/cyclic nucleotide pathway in human platelets via an osmotic mechanism. Thromb Haemost 2005;93:517–526
- Sudic D, Razmara M, Forslund M, Ji Q, Hjemdahl P, Li N. High glucose levels enhance platelet activation: involvement of multiple mechanisms. Br J Haematol 2006;133:315–322
- Hajek AS, Joist JH. Platelet insulin receptor. Methods Enzymol 1992;215:398–403
- Ferreira IA, Eybrechts KL, Mocking AI, Kroner C, Akkerman JW. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem 2004;279:3254–3264
- Hunter RW, Hers I. Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function. J Thromb Haemost 2009;7:2123–2130
- Yngen M, Li N, Hjemdahl P, Wallén NH. Insulin enhances platelet activation in vitro. Thromb Res 2001;104:85–91
- Anfossi G, Massucco P, Mattiello L, et al. Insulin exerts opposite effects on platelet function at physiological and supraphysiological concentrations. Thromb Res 1996;82:57–68
- Ferreira IA, Mocking AIM, Feijge MA, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006;26:417–422
- Murer EH, Gyda MA, Martinez NJ. Insulin increases the aggregation response of human platelets to ADP. Thromb Res 1994;73:69–74
- Rauchfuss S, Geiger J, Walter U, Renne T, Gambaryan S. Insulin inhibition of platelet-endothelial interaction is mediated by insulin effects on endothelial cells without direct effects on platelets. J Thromb Haemost 2008;6:856–864
- Westerbacka J, Yki-Järvinen H, Turpeinen A, et al. Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 2002;22:167–172
- Gerrits AJ, Koekman CA, van Haeften TW, Akkerman JW. Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin. Diabetes 2010;59:1487–1495
- Mellbin LG, Malmberg K, Norhammar A, Wedel H, Rydén L, DIGAMI 2 Investigators The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008;29:166–176
- Angiolillo DJ, Bernardo E, Ramírez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006;48:298–304
Source: PubMed